Aurobindo Pharma: Transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas…
Aurobindo Pharma (AUROPHARMA) filed a disclosure titled "Transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company". The company is valued at about ₹98,102…
What happened
Aurobindo Pharma (AUROPHARMA) filed a disclosure with the exchanges on 4 November 2026 at 08:31 PM titled "Transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company".
Company snapshot
Aurobindo Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹98,102 crore.
The stock last traded at ₹1,705, against a 52-week range of ₹1,106–₹1,740 (2.0% below the high).
Before this filing the shares had moved +1.1% over the month and +6.8% over three months. Average daily turnover over the last 20 sessions was about ₹137 crore.
Promoters held 51.88% at the end of Q1 FY27, up 0.06% points from the previous quarter; 13.75% of promoter shares were pledged. Foreign institutions owned 16.38% and domestic institutions 25.10%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 7,868 | 824.8 | 14.2 |
| Q2 FY26 | 8,286 | 848.5 | 14.61 |
| Q3 FY26 | 8,646 | 910.3 | 15.67 |
| Q4 FY26 | 8,853 | 921.3 | 15.86 |
| Q1 FY27 | 9,150 | 1,032.6 | 17.86 |
What history shows
BCEIE's records show 12 or more previous m&a filings from the company since May 2026.
After those filings, the stock fell 0.1% on average the next trading day and was up 1.6% on average after five days (10 filings with price data).
Across 150 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +0.9% over five days; 59% of them rose the next day.
Market-wide, 2,343 m&a filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 2 Oct 2026 | Completion of acquisition. | +1.0% | +1.8% |
| 2 Oct 2026 | M&A | +1.0% | +1.8% |
| 1 Oct 2026 | M&A | +0.2% | — |
| 12 Sept 2026 | M&A | −1.2% | +2.0% |
| 1 Sept 2026 | Incorporation of a new wholly owned subsidiary by the name of… | −4.0% | −1.5% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
- 4 November 2026: Board meeting — Financial Results/Dividend.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.